SEP 1 6 2004

PART B - FEE(S) TRANSMITTAL

Complete agir send this form, together with applicable fee(s), to: Mall

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

7590

06/16/2004

VERTEX PHARMACEUTICALS INC. 130 Waverly Street Cambridge, MA 02139-4242 Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Karen DiRogro/)	(Depositor's name
Marin Diraces	(Signature
September 16, 2004	(Date

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONS		
09/941,282	08/28/2001	Pravin Chaturvedi	VPI/01-119	8388

TITLE OF INVENTION: OPTIMAL COMPOSITIONS AND METHODS THEREOF FOR TREATING HCV INFECTIONS

	SMALL ENTITY	ISSUE F	EE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$133)	\$300	\$1630	09/16/2004
EXAMINER		ART UNIT		CLASS-SUBCLASS	7 ·	
ANDRES, JANET L		1646	514-002000		•	
Address form PTO/SB/1: O "Fee Address" indicati	ènce address (or Change of	Correspondence	names of agents Of firm (hav agent) an	inting on the patent front page f up to 3 registered patent a R, alternatively, (2) the name ing as a member a registered d the names of up to 2 registor or agents. If no name is listed;	of a single attorney or tered patent	l C. Badia Pharmaceutica orated
PLEASE NOTE: Unless	an assignee is identified be d to the USPTO or is being	low, no assignee di submitted under sej	ata will appe parate cover.	I (print or type) ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO	l'a substitute for filing an assi	te when an assignment has gnment.
(A) NAME OF ASSIGN	an assignee is identified be d to the USPTO or is being	low, no assignee de submitted under sej (B	ata will appe parate cover.	ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO	l'a substitute for filing an assi	ate when an assignment has grament.
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN	an assignee is identified be d to the USPTO or is being EE	low, no assignee d submitted under sej (B rporated	ata will appe parate cover, RESIDENO	ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO Cambridge,	f a substitute for filing an assi UNTRY) Massachusetts	02139-4242
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN: Vertex Pharma: Please check the appropriate	an assignee is identified be d to the USPTO or is being EE Ceuticals Inco	low, no assignee di submitted under sej (B rporated pries (will not be pri	ata will appe parate cover, RESIDENO	ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO Cambridge, atent);	i a substitute for filing an assi UNTRY)	02139-4242
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN: Vertex Pharma: Please check the appropriate	an assignee is identified be d to the USPTO or is being EE Ceuticals Inco	low, no assignee disubmitted under sej (B rporated pries (will not be pri	ata will appe parate cover,) RESIDENO nted on the p	ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO Cambridge, atent);	a substitute for filing an assi UNTRY) Massachusetts corporation or other private gro	02139-4242
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGNI Vertex Pharma: Please check the appropriate to the following fee(s) are	an assignee is identified be d to the USPTO or is being EE Ceuticals Inco	clow, no assignee disubmitted under sej (B rporated pries (will not be pri 4b	ata will appearance cover. RESIDENO nted on the parameter of Q A check in	ar on the patent. Inclusion of a Completion of this form is NO CE: (CITY and STATE OR CO Cambridge, natent); individual 55 of Fec(s):	I a substitute for filing an assi UNTRY) Massachusetts corporation or other private greaters.	02139-4242

(Authorized Signature) Wichael C. Badia		(Date)			
			51,424	9/16/2004	
NOTE; The Issue Fee and Put	lication Fee	(if re	outred) will not	be accepted from anyone	

NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it displays a valid OMB control number.

09/17/2004 RMEBRAH1 00000130 500725 09941282

01 FC:1501 1330.00 DA 02 FC:1504 300.00 DA 03 FC:8001 30.00 DA

TRANSMIT THIS FORM WITH FEE(S)



Vertex Pharmaceuticals Incorporated

130 Waverly Street • Cambridge, MA 02139-4242 Tel. 617.444.6100 • Fax 617.444.6483

http://www.vrtx.com

Fax Message

TO:	Examiner Janet L. Andres
APPLICATION NO.:	09/941,282
CONFIRMATION NO.:	8388
FAX:	(703) 746-4000
FROM:	Michael C. Badia
DATE:	September 16, 2004
SUBJECT:	Attorney Docket No. VPI/01-119 US
TOTAL # OF PAGES:	3

Message or Comment:

Attached are the following documents:

1. Issue Fee (in duplicate).

The Commissioner is hereby authorization to charge deposit account 50-0725 in the amount of \$1,330.00 to cover the cost of the Issue Fee.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, and any documents referred to as attached hereto, is being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 746-4000 on this 16th day of September 2004.

Karen DiRocco

If any problems occur with this fax transmittal, please call (617) 444-6467 immediately.

FAX Number (617) 444-6483 Legal Department

CONFIDENTIALITY NOTICE

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person (a) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.